[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100450590":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":28,"locations":38,"responsibleParty":181,"collaborators":19,"id":183,"slug":184,"hasResults":185,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":19,"eligibilityCriteria":189,"healthyVolunteers":185,"sex":190,"minAge":191,"maxAge":19,"enrollmentInfo":192,"targetDuration":19,"studyType":195,"phases":196,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":41,"whyStopped":19,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"APG-2575 single agent in Relapse\u002FRefractory CLL\u002FSLL","EXPERIMENTAL","APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.",[13],"Drug: APG2575",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","APG2575",[9],null,[21,24],{"name":22,"affiliation":5,"role":23},"Yifan Zhai, M.D., Ph.D.","STUDY_DIRECTOR",{"name":25,"affiliation":26,"role":27},"Jianyong Li, M.D.","The First Affiliated Hospital with Nanjing Medical University","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":19,"email":33},"Zi Chen, Doctor","CONTACT","+8618117275173","Zi.Chen@ascentage.com",{"name":35,"role":31,"phone":36,"phoneExt":19,"email":37},"Min Yu, Doctor","+8615000679101","Min.Yu@ascentage.com",[39,57,68,79,93,107,121,135,144,158,172],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":48,"coordinates":49},"Point",[50,51],113.25,23.11667,{"lat":51,"lon":50},[54,56],{"name":55,"role":31,"phone":19,"phoneExt":19,"email":19},"Yang Liang, Postdoc",{"name":55,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":58,"status":59,"city":42,"state":43,"zip":60,"country":45,"countryCode":46,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Zhujiang Hospital of Southern Medical University","NOT_YET_RECRUITING","510280",{"type":48,"coordinates":62},[50,51],{"lat":51,"lon":50},[65,67],{"name":66,"role":31,"phone":19,"phoneExt":19,"email":19},"Rui Huang, M.D., Ph.D.",{"name":66,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":69,"status":41,"city":42,"state":43,"zip":70,"country":45,"countryCode":46,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Nanfang Hospital of Southern Medical University","510515",{"type":48,"coordinates":72},[50,51],{"lat":51,"lon":50},[75,77],{"name":76,"role":31,"phone":19,"phoneExt":19,"email":19},"Ru Feng",{"name":78,"role":27,"phone":19,"phoneExt":19,"email":19},"Ru Feng, M.D.",{"facility":80,"status":59,"city":81,"state":82,"zip":83,"country":45,"countryCode":46,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Hainan General Hospital","Haikou","Hainan","570311",{"type":48,"coordinates":85},[86,87],110.34651,20.03421,{"lat":87,"lon":86},[90,92],{"name":91,"role":31,"phone":19,"phoneExt":19,"email":19},"Li'e Lin, M.D.",{"name":91,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":94,"status":41,"city":95,"state":96,"zip":97,"country":45,"countryCode":46,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Henan Cancer Hospital","Zhengzhou","Henan","450003",{"type":48,"coordinates":99},[100,101],113.64861,34.75778,{"lat":101,"lon":100},[104,106],{"name":105,"role":31,"phone":19,"phoneExt":19,"email":19},"Keshu Zhou, M.D., Ph.D.",{"name":105,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":108,"status":41,"city":109,"state":110,"zip":111,"country":45,"countryCode":46,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Union Hospital medical college Huazhong University of Science and Technology","Wuhan","Hubei","430022",{"type":48,"coordinates":113},[114,115],114.26667,30.58333,{"lat":115,"lon":114},[118,120],{"name":119,"role":31,"phone":19,"phoneExt":19,"email":19},"Guohui Cui, M.D.",{"name":119,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":122,"status":59,"city":123,"state":124,"zip":125,"country":45,"countryCode":46,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"The First Affilated Hospital of Soochow University","Suzhou","Jiangsu","215006",{"type":48,"coordinates":127},[128,129],120.59538,31.30408,{"lat":129,"lon":128},[132,134],{"name":133,"role":31,"phone":19,"phoneExt":19,"email":19},"Caixia Li, M.D., Ph.D.",{"name":133,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":136,"status":59,"city":123,"state":124,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":137,"geoPoint":139,"contacts":140},"People's hospital of Jiangsu Province",{"type":48,"coordinates":138},[128,129],{"lat":129,"lon":128},[141,143],{"name":25,"role":31,"phone":19,"phoneExt":19,"email":142},"lijianyonglm@medmail.com.cn",{"name":25,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":145,"status":59,"city":146,"state":147,"zip":148,"country":45,"countryCode":46,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"The First Affilated Hospital of Nanchang University","Nanchang","Jiangxi","330006",{"type":48,"coordinates":150},[151,152],115.85306,28.68396,{"lat":152,"lon":151},[155,157],{"name":156,"role":31,"phone":19,"phoneExt":19,"email":19},"Fei Li, M.D., Ph.D.",{"name":156,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":159,"status":59,"city":160,"state":161,"zip":162,"country":45,"countryCode":46,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Institute of blood transfusion of Chinese Academy of Medical Sciences","Tianjin","Tianjin Municipality","215127",{"type":48,"coordinates":164},[165,166],117.17667,39.14222,{"lat":166,"lon":165},[169,171],{"name":170,"role":31,"phone":19,"phoneExt":19,"email":19},"Tingyu Wang, M.D., Ph.D.",{"name":170,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":173,"status":59,"city":174,"state":175,"zip":176,"country":45,"countryCode":46,"cosmosGeoPoint":19,"geoPoint":19,"contacts":177},"The First Affiliated Hospital of Zhejiang University School of Medicine","Hanzhou","Zhejiang","310003",[178,180],{"name":179,"role":31,"phone":19,"phoneExt":19,"email":19},"Jie Jin, M.D., Ph.D.",{"name":179,"role":27,"phone":19,"phoneExt":19,"email":19},{"type":182,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100450590","phase-2-study-of-apg-2575-in-patients-with-relapsedrefractory-cllsll-100450590",false,"NCT05147467","Study of APG-2575 in Patients With Relapsed\u002FRefractory CLL\u002FSLL","A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Inclusion Criteria:\n\nSubjects who meet each of the following inclusion criteria are eligible to participate in this study:\n\n1. Age ≥18 years old.\n2. Pathologically confirmed CLL\u002FSLL according to the 2018 revised IWCLL NCI-WG guidelines, subject with measurable lesions or splenomegaly due to CLL.\n3. Expected survival is at least 12 weeks.\n4. Refractory, recurrent, or intolerant to BTK inhibitors and immunochemotherapy,or first-line treatment with BTK inhibitors fails and is not suitable for immunochemotherapy.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2.\n6. Ability to understand and willingness to sign a written informed consent form approved by EC committee (the consent form must be signed by the patient prior to any screening or study-specific procedures).\n7. Willingness and ability to comply with study procedures and follow-up examination.\n\nExclusion Criteria:\n\nSubjects who meet any of the following exclusion criteria are not to be enrolled in this study:\n\n1. Prior history of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy or autologous hematopoietic stem cell transplantation within 24 months.\n2. Failure to recover adequately, at the discretion of the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.\n3. Received Bcl-2 inhibitor treatment.\n4. Invasive NHL transformation or central nervous system (CNS) involvement has occurred.\n5. Pregnancy or lactation, or pregnancy is expected during the study period or within 3 months after the last administration of treatment.\n6. Within 2 years before entering the study, the subject had a history of active malignant tumors other than CLL \u002F SLL, except that:\n\n   * Fully treated cervical carcinoma in situ;\n   * Completely resected basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\n   * Confinement and resection of previously cured malignancies (or other treatment).\n7. Any other condition or circumstance that would, at the discretion of the investigator, make the patient unsuitable for participation in the study.","ALL","18 Years",{"count":193,"type":194},75,"ESTIMATED","INTERVENTIONAL",[197],"PHASE2","The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed\u002Frefractory CLL\u002FSLL.",[200,201],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[200,201,203,204],"APG-2575","Lisaftoclax","2026-03-24",{"date":207,"type":208},"2026-03-27","ACTUAL",{"date":210,"type":208},"2021-12-28",{"date":212,"type":194},"2027-12",{"name":5,"class":6},11]